v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development $ 989 $ 2,983
General and administrative 7,463 7,121
Total operating expenses 8,452 10,104
Loss from operations (8,452) (9,921)
Other (expense) income:    
Derecognition of Mabwell liability (see Note 19) 3,300
Gain on reversal of excise taxes payable (see Note 10) 4,401
Other income (see Note 2) 3,556
Change in fair value of forward purchase agreement asset (23) (339)
Change in fair value of SEPA put rights asset (92) (312)
Change in fair value of embedded derivative liability (773) (11)
Gain on extinguishment of accrued liabilities 200 173
Loss on settlement of convertible notes (358)
Interest income 33 9
Interest expense (1,128) (387)
Total other income, net 5,560 2,689
Net loss (2,892) (7,232)
Deemed dividend resulting from the warrant down round (10,177)
Net loss attributable to common stockholders $ (2,892) $ (17,409)
Loss per share    
Basic (in Dollars per share) $ (1.3) $ (22.31)
diluted (in Dollars per share) $ (1.3) $ (22.31)
Weighted average shares outstanding - basic (in Shares) 2,232,610 780,332
Weighted average shares outstanding - diluted (in Shares) 2,232,610 780,332
Research and development services    
Revenue:    
Research and development services $ 183